Skip to main content
    N

    NRX Pharmaceuticals Inc (NRXP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.15
    -0.04 (-1.83%)

    Market Cap: $95.58M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    NRX Pharmaceuticals Inc (NRXP) Financials: Revenue, Profit and Cash Flow

    Updated Aug 14, 2026. Financial statements from company filings, amounts in US dollars.

    NRX Pharmaceuticals reported revenue of $1.23M for the fiscal year ended Dec 31, 2025. That year, net income was -$28.62M with a net margin of -2336.5%, operating cash flow was -$14.11M and free cash flow was -$14.11M. The quarter ended Jun 30, 2026 had revenue of $1.10M and net income of -$16.52M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.23MN/A58.8%-1324.4%-2336.5%
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Dec 2018N/AN/AN/AN/AN/A
    Dec 2017N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$1.23M$0$0$0$0$0N/AN/AN/A
    Cost of revenue$505.00K$5.00K$5.00K$4.00K$2.00K$2.00KN/A$1.01MN/A
    Gross profit$720.00K-$5.00K-$5.00K-$4.00K-$2.00K-$2.00KN/A-$1.01MN/A
    Research and development$3.78M$6.20M$13.37M$17.03M$20.26M$10.63M$0$0$0
    Operating income-$16.22M-$19.70M-$27.59M-$44.34M-$95.20M-$22.06M-$713.19K-$1.01M-$134.48K
    Net income-$28.62M-$25.13M-$30.15M-$39.75M-$93.06M-$51.78M$408.43K$66.10K-$105.00K
    EBITDAN/AN/AN/A-$39.75M-$93.04MN/A$492.63K$82.41K-$105.00K
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$1.10M$1.07M$983.00K$242.00K$0$4.00K$4.00K$0$0$8.00K$8.00K$0
    Gross profit$258.00K$272.00K$475.00K$104.00K$0$2.00K-$1.00K-$2.00K-$1.00K-$1.00K-$1.00K-$2.00K
    Operating income-$6.50M-$4.75M-$4.59M-$4.12M-$3.73M-$3.85M-$3.63M-$3.02M-$7.05M-$6.00M-$4.41M-$5.81M
    Net income-$16.52M-$1.43M$360.00K-$5.89M-$17.58M-$5.51M-$9.08M-$1.62M-$7.90M-$6.53M-$4.33M-$6.06M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $316.00K by $7.48M. Shareholder equity was negative, at -$15.94M, as total liabilities of $28.89M exceeded total assets of $12.96M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$12.96M$3.65M$7.32M$25.82M$32.73M$2.94M$32.07M$70.80M$69.57M
    Current assets$8.89M$3.30M$6.88M$25.80M$32.71M$2.93M$69.49K$30.19K$536.38K
    Cash and equivalents$7.80M$1.44M$4.59M$20.05M$27.61M$1.86M$6$11.08K$449.37K
    Total liabilities$28.89M$26.87M$19.05M$18.41M$11.92M$46.71M$2.57M$1.26M$93.17K
    Short-term debt$316.00K$1.57M$9.16M$7.70M$518.00K$249.00KN/AN/AN/A
    Long-term debtN/A$5.01MN/A$2.82MN/A$2.67M$1.95M$690.00KN/A
    Shareholder equity-$15.94M-$23.22M-$11.73M$7.41M$20.81M-$43.77M$29.50M$69.54M$69.47M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$34.16M$11.90M$12.96M$15.00M$4.84M$7.59M$3.65M$4.46M$5.26M$3.79M$7.32M$13.11M
    Total liabilities$34.33M$25.72M$28.89M$40.75M$40.45M$32.75M$26.87M$23.28M$23.66M$18.86M$19.05M$19.33M
    Cash and equivalents$26.69M$6.71M$7.80M$7.18M$2.91M$5.55M$1.44M$1.65M$1.90M$1.32M$4.59M$8.90M
    Shareholder equity-$170.00K-$13.82M-$15.94M-$25.75M-$35.62M-$25.16M-$23.22M-$18.82M-$18.39M-$15.07M-$11.73M-$6.22M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$14.11M-$10.64M-$21.66M-$39.76M-$37.70M-$2.27M-$792.73K-$473.19K-$135.81K
    Capital expenditures$0$0$3.00K$10.00K$7.00K$2.00K$1$0$0
    Free cash flow-$14.11M-$10.64M-$21.66M-$39.77M-$37.71M-$2.27M-$792.73K-$473.19K-$135.81K
    Investing cash flow-$2.81MN/A-$3.00K-$10.00K-$7.00K-$2.00K$40.25M-$647.61K-$69.00M
    Financing cash flow$23.28M$7.49M$6.20M$32.21M$63.46M$3.25M-$39.46M$682.50K$69.59M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$8.88M-$4.29M-$3.71M-$2.89M-$4.03M-$3.48M-$2.10M-$2.31M-$3.50M-$3.67M-$3.19M-$4.56M
    Capital expenditures$897.00K$0$0$0$0$0$0$0$0$1.00K$4.00K$2.00K
    Free cash flow-$9.77M-$4.29M-$3.71M-$2.89M-$4.03M-$3.48M-$2.10M-$2.31M-$3.50M-$3.67M-$3.20M-$4.57M
    Last 12 quarters

    Frequently Asked Questions About NRXP

    What is NRX Pharmaceuticals' annual revenue?

    NRX Pharmaceuticals reported revenue of $1.23M for the fiscal year ended Dec 31, 2025.

    Is NRX Pharmaceuticals profitable?

    No. NRX Pharmaceuticals reported net income of -$28.62M for the fiscal year ended Dec 31, 2025, with a net margin of -2336.5%.

    How much free cash flow does NRXP generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$14.11M minus capital expenditures of $0 produced free cash flow of -$14.11M.

    How much debt does NRX Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $316.00K and cash and equivalents of $7.80M.

    What is NRXP's profit margin?

    For the fiscal year ended Dec 31, 2025, NRX Pharmaceuticals reported gross margin of 58.8%, operating margin of -1324.4% and net margin of -2336.5%.